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Abstract
Background:  Untreated  celiac  disease  has  traditionally  been  linked  to  a  greater  risk  for  small
intestinal  bacterial  overgrowth,  but  the  existing  evidence  is  inconclusive.
Aims: To  compare  the  prevalence  of  small  intestinal  bacterial  overgrowth  in  subjects  with  celiac
disease compared  with  control  subjects  and  patients  with  irritable  bowel  syndrome.
Material  and  methods:  The  study  included  15  untreated  celiac  disease  patients,  15  subjects
with irritable  bowel  syndrome,  and  15  healthy  controls.  All  enrolled  patients  underwent  a
lactulose  breath  test  measuring  hydrogen  and  methane.  Small  intestinal  bacterial  overgrowth
was deﬁned  according  to  previously  published  criteria.
Results:  No  differences  were  found  in  relation  to  age  or  sex.  The  prevalence  of  small  intestinal
bacterial  overgrowth  was  similar  between  the  celiac  disease  patients  and  the  controls  (20  vs.
13.33%, P  =  NS),  whereas  it  was  higher  in  patients  with  irritable  bowel  syndrome  (66.66%,  P  <  05).
Conclusion:  There  was  no  difference  in  the  prevalence  of  small  intestinal  bacterial  overgrowth
between the  untreated  celiac  disease  patients  and  healthy  controls.
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La  prevalencia  de  sobrecrecimiento  bacteriano  en  celíacos  es  similar  a  la  de  sujetos
sanos  y  menor  que  en  pacientes  con  síndrome  de  intestino  irritable
Resumen
Introducción:  Clásicamente,  se  ha  vinculado  a  la  enfermedad  celíaca  no  tratada  con  un  mayor
riesgo de  sobrecrecimiento  bacteriano.  Sin  embargo,  la  evidencia  existente  no  es  concluyente.
Objetivo: Comparar  la  prevalencia  de  sobrecrecimiento  bacteriano  en  sujetos  celíacos  con
respecto  a  sujetos  controles  y  a  pacientes  con  síndrome  de  intestino  irritable.
Material y  método: Fueron  inscritos  15  pacientes  celíacos  no  tratados,  15  sujetos  con  síndrome
de intestino  irritable  y  15  sujetos  controles  sanos.  Los  pacientes  inscritos  realizaron  un  test  de
hidrógeno/metano  en  aire  espirado  con  lactulosa.  Se  deﬁnió  al  sobrecrecimiento  bacteriano
según criterios  previamente  publicados.
Resultados:  No  se  encontraron  diferencias  en  cuanto  a  edad  y  sexo.  La  prevalencia  de
sobrecrecimiento  bacteriano  fue  similar  entre  celíacos  y  controles  (20  vs.  13.33%,  p  =  NS),
mientras que  fue  mayor  en  pacientes  con  síndrome  de  intestino  irritable  (66.66%,  p  <  0.05).
Conclusión:  Los  celíacos  no  tratados  presentan  una  prevalencia  de  sobrecrecimiento  bacteriano
no diferente  a  los  sujetos  sanos.
©  2015  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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eliac  disease  is  an  immunologic  disorder  in  which  an
nﬂammatory  alteration  is  produced  due  to  exposure  to
luten,  with  varying  degrees  of  villous  atrophy  and  nutrient
alabsorption.1 Current  treatment  consists  of  a  gluten-free
iet.
Untreated  and/or  refractory  celiac  disease  has  tradi-
ionally  been  linked  to  a  greater  risk  for  developing  small
ntestinal  bacterial  overgrowth,  but  conclusive  evidence
ith  respect  to  this  is  lacking.2,3
Small  intestinal  bacterial  overgrowth  diagnosis  is  difﬁ-
ult.  A  noninvasive  alternative  is  the  hydrogen/methane
reath  test.4 Its  usefulness  for  this  purpose  is  controver-
ial  because  of  the  inﬂuence  of  bowel  transit  time  on  the
esults.  Nevertheless,  it  continues  to  be  a  widely  used  tool
n  clinical  practice.
The  evidence  with  respect  to  the  prevalence  of  small
ntestinal  bacterial  overgrowth  measured  by  breath  test  in
eliac  disease  subjects  is  scarce  and  contrasting.  Therefore
ur  aim  was  to  compare  the  results  of  said  test  in  celiac
isease  subjects  with  those  of  healthy  controls  and  patients
ith  irritable  bowel  syndrome  (IBS)  in  whom  such  alteration
s  frequently  observed.5
ethods
atient  selection
atients  above  the  age  of  18  years  that  were  seen  at  the
astroenterology  Section  of  our  institution  within  the  time
rame  of  January  2013  and  December  2014  were  evalu-
ted.  On  the  one  hand,  subjects  were  enrolled  that  had  a
ecent  diagnosis  of  celiac  disease  and  that  had  not  yet  begun
reatment  with  a  gluten-free  diet.  Celiac  disease  patients
ere  deﬁned  as  those  patients  with  positive  IgA  or  IgG
e
e
tnti-tissue  transglutaminase  and/or  anti-endomysial  anti-
odies,  together  with  a  duodenal  biopsy  showing  signs  of
illous  atrophy  (Marsh  III).
On  the  other  hand,  subjects  were  enrolled  that  had  IBS
iagnosis  without  constipation  and  that  were  negative  for
eliac  disease  antibodies.  IBS  was  deﬁned  in  accordance
ith  the  Rome  III  criteria.6 And  ﬁnally,  healthy  subjects  seen
t  our  institution  for  preventive  clinical  control  were  invited
o  participate  if  they  did  not  present  with  digestive  symp-
oms  and  were  negative  for  celiac  disease  antibodies.  The
ubjects  were  enrolled  in  a  1:1:1  ratio.
Those  subjects  suspected  of  concomitant  digestive  dis-
ase,  that  were  pregnant,  and  patients  that  had  taken
ntibiotics  or  probiotics  within  the  last  30  days  or  prokinetics
n  the  last  2  weeks,  were  excluded  from  the  study.
reath  test
nce  the  written  statements  of  informed  consent  were
igned,  the  enrolled  subjects  were  given  a  hydro-
en/methane  breath  test  utilizing  lactulose  as  a  substrate.
he  celiac  disease  subjects  took  the  test  before  begin-
ing  the  gluten-free  diet.  The  tests  were  performed  using
he  previously  described  technique:7 after  the  subjects
asted  for  12  h  and  were  on  a  low  fermentable  carbohy-
rate  diet,  they  provided  breath  samples  before  (baseline
ample)  and  after  ingesting  10  ml  of  lactulose  every  20  min
or  180  min.  The  samples  were  analyzed  with  a  chromato-
raph  (BreathTracker®  SC.  QuinTron  Instruments  Company;
ilwaukee,  WI,  USA)  to  determine  the  excreted  hydrogen
nd  methane  concentrations,  which  were  measured  in  par-
icles  per  million  (ppm).  Curves  were  drawn  illustrating  the
xcreted  gas  concentrations  in  relation  to  time.
The  presence  of  anomalous  hydrogen  and/or  methane
xcretion  considered  consistent  with  small  intestinal  bac-
erial  overgrowth  was  evaluated  for  each  case.  Any  of  the
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Table  1  Comparison  of  the  study  group  characteristics.
Celiac  disease
patients  (n  =  15)
IBS  patients
(n  =  15)
Control  subjects
(n =  15)
p  value
Agea 40  ±  13  41  ±  14  49  ±  18  NS
Male sex  percentage  26.66  26.66  40  NS
Small intestinal  bacterial  overgrowth  percentage  20  66.66  13.33  <  0.05
High baseline  excretion  percentage  26.66  13.33  6.66  NS
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oNS: not signiﬁcant; IBS: irritable bowel syndrome.
a Results expressed as mean ± standard deviation.
following  ﬁndings  were  regarded  as  abnormal:  a)  hydrogen
excretion  greater  than  20  ppm  before  90  min  or  an  initial
peak  of  12  ppm  before  90  min  followed  by  a  decrease  of  at
least  5  ppm  and  a  later  increase  (double  hydrogen  peak),
and  b)  an  increase  in  methane  excretion  greater  than  3  ppm
at  any  time  during  the  test.
In  addition,  the  presence  of  an  elevated  baseline  value
of  hydrogen  and/or  methane  (value  greater  than  3  ppm  of
methane  and  12  ppm  of  hydrogen)  was  registered.
Statistical  analysis
Statistical  analysis  was  carried  out  using  the  Stata®  version
11.1  statistics  program  (Statacorp,  College  Station;  Texas,
USA).  Numerical  values  were  described  as  means  with  their
standard  deviations.  Categorical  variables  were  described
as  percentages.  The  ANOVA  test  was  utilized  for  the  numer-
ical  variable  comparison  and  the  Fisher  test  for  comparing
the  categorical  variables.  Odds  ratios  (OR)  were  calculated
with  their  corresponding  95%  conﬁdence  intervals  (95%  CI).
Statistical  signiﬁcance  was  set  at  a  value  of  p  less  than  0.05.
Results
A  total  of  15  recently  diagnosed  celiac  disease  patients,  15
patients  with  IBS,  and  15  healthy  controls  were  enrolled  in
the  study.  Table  1  shows  the  comparison  of  the  demographic
data,  as  well  as  the  prevalence  of  small  intestinal  bacterial
overgrowth  measured  by  breath  test  by  group.
There  was  signiﬁcant  difference  in  small  intestinal  bac-
terial  overgrowth  prevalence  in  IBS  subjects  with  respect  to
the  other  2  groups  (66.66  vs.  20%  in  celiac  disease  patients
and  13.33%  in  the  controls).  This  difference  presenting
in  the  IBS  patients  was  signiﬁcant  when  compared  with  both
the  celiac  disease  group  (OR  8  [1.52-42.01],  p  =  0.02)  and
the  control  group  (OR  13  [2.07-81.48],  p  =  0.007).  No  dif-
ferences  were  found  between  the  celiac  disease  patients
and  the  controls  (OR  1.62  [0.23-11.46],  p  =  NS).  Even  though
the  difference  was  not  statistically  signiﬁcant,  the  celiac
disease  patients  presented  with  a  greater  frequency  of  ele-
vated  baseline  values  compared  with  the  other  groups.
The  patients  that  presented  with  a  positive  test  for  small
intestinal  bacterial  overgrowth  with  compatible  digestive
symptoms  were  treated  with  1,200  mg/day  of  rifaximin  for
2  weeks.  Two  weeks  after  having  ﬁnished  treatment,  77%
of  the  patients  had  complete  symptom  resolution.  No  sig-
niﬁcant  differences  were  found  in  relation  to  the  antibiotic
response  between  the  evaluated  groups.
t
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discussion
n  accordance  with  our  results,  there  was  no  difference
n  small  intestinal  bacterial  overgrowth  prevalence  mea-
ured  through  breath  test  between  untreated  celiac  disease
atients  and  healthy  controls,  but  there  was  increased
revalence  in  the  IBS  subjects.
There  is  evidence  as  to  a  relation  between  altered  breath
est  results  in  an  IBS  context  and  small  intestinal  bacterial
vergrowth  prevalence  measured  by  this  method  in  more
han  80%  of  the  cases.5 In  a  celiac  disease  context,  there  is
ar  less  evidence.
In this  sense,  Corazza  et  al.8,9 have  observed  an  increase
n  the  baseline  value  of  hydrogen  in  untreated  celiac
isease  subjects;  this  alteration  was  corrected  with  a
luten-free  diet.  On  the  other  hand,  Chang  et  al.2 found
o  signiﬁcant  differences  in  hydrogen  excretion  between
eliac  disease  patients  and  controls.  Our  experience  with
ntreated  active  celiac  disease  patients  was  that  hydro-
en  values  were  not  different,  compared  with  those  of
he  controls,  and  they  were  signiﬁcantly  lower  when  com-
ared  with  the  IBS  subjects.  Celiac  disease  patients  present
ith  intestinal  motility  alterations  that  can  predispose  to
mall  intestinal  bacterial  overgrowth;  nevertheless,  preva-
ence  is  variable.  Most  likely  small  intestinal  bacterial
vergrowth  prevalence  is  greater  in  celiac  disease  patients
ith  digestive  symptoms  related  to  gases.  Therefore,  it
s  to  be  expected  that  in  an  unselected  celiac  disease
atient  population,  prevalence  would  be  similar  to  that
f  the  general  population,  as  was  shown  in  our  study.
he  addition  of  excreted  methane  values  provides  a  more
omplete  perspective  to  previous  studies  that  suggested
hese  ﬁndings,  only  measuring  hydrogen  in  the  breath
est.
Although  the  value  of  the  lactulose  breath  test  for  small
ntestinal  bacterial  overgrowth  diagnosis  is  debatable,  it  is
ndeniable  that  the  difference  in  hydrogen  and  methane
xcretion  reﬂects  a  difference  in  the  fermentative  capac-
ty  of  non-absorbable  substrates  on  the  part  of  the  gut
icrobiota,  regardless  of  whether  or  not  this  results  in
ctual  small  intestinal  bacterial  overgrowth.  Thus,  our  expe-
ience  was  valuable  in  that  we  found  a  difference  between
atients  with  celiac  disease  and  healthy  controls  in  rela-
ion  to  patients  with  IBS.  The  relatively  small  sample  size
f  our  patient  population  should  be  underlined  as  a  limita-
ion  of  our  study,  as  well  as  the  fact  that  the  patients  did
ot  undergo  a  duodenal  aspirate  culture.  Even  though  it  is
egarded  as  the  criterion  standard  diagnostic  test,  it  can  be
ifﬁcult  to  reproduce.
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In  conclusion,  the  patients  with  untreated  celiac  disease
resented  with  hydrogen  and  methane  excretion  proﬁles
onsistent  with  small  intestinal  bacterial  overgrowth  that
ere  similar  to  those  of  subjects  with  no  digestive  disorders,
ut  signiﬁcantly  different  from  those  of  patients  with  IBS.
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